Perampanel (Fycompa): A Review of Clinical Efficacy and Safety in Epilepsy

Jessica Greenwood et al. P T. 2016 Nov.

. 2016 Nov;41(11):683-698.

Abstract

Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy.

1. Frampton JE. Perampanel: a review in drug-resistant epilepsy. Drugs. 2015;75(14):1657–1668. doi: 10.1007/s40265-015-0465-z. - DOI - PubMed
1. Ali R, Connolly ID, Feroze AH, et al. Epilepsy: a disruptive force in history. World Neurosurg. 2016;90:685–690. doi: 10.1016/j.wneu.2015.11.060. - DOI - PubMed
1. Bush MA, Franco S. QuickStats: age-adjusted percentages of adults aged ≥18 years who have epilepsy, by epilepsy status and race/ethnicity—National Health Interview Survey, United States, 2010 and 2013 combined. MMWR Morb Mortal Wkly Rep. 2016;65:611. doi: http://dx.doi.org/10.15585/mmwr.mm6523a8. - DOI - PubMed
1. Walsh S, Donnan J, Fortin Y, et al. A systematic review of the risks factors associated with the onset and natural progression of epilepsy. Neurotoxicology. 2016 Mar 19; doi: 10.1016/j.neuro.201603.011. pii: S0161-813X(16)30030-4. [Epub ahead of print.] - DOI - PubMed
1. Engelborghs S, D’Hooge R, De Deyn PP. Pathophysiology of epilepsy. Acta Neurol Belg. 2000;100(4):201–213. - PubMed